# Ainos, Inc.

**AIMDW**

Nasdaq; business equipment; SIC 3577, Computer Peripheral Equipment, NEC; CIK 0001014763


# None

**No letter**

6 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $20.9M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | short runway, thin data<br>not computable: dilution, distress, fortress balance sheet |
| **Inputs computable** | 6 of 14 |
| **Graded from** | filings received through Mar 30, 2026<br>221 days before the rescan; latest periodic filing 10-Q received Aug 3, 2026 |
| **Last close** | $0.11<br>2026-06-02; market equity $0; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 30, 2026*

Inc. (the "Company"), incorporated in the State of Texas in 1984, is a dual-platform company advancing artificial intelligence-based smelltech technologies and immune therapeutics. Our primary strategic focus is the commercialization of our proprietary scent digitization platform, AI Nose, while we also continue to develop therapeutic assets based on our low-dose oral interferon program, VELDONA®.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 50.8** | | | | | | |
| Gross profitability | 0.5% | 28.7% | | 93.8 | 555 | 2025-12-31 |
| Return on invested capital | not computable | 11.4% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (40.9%) | (7.3%) | | 7.9 | 618 | 2025-12-31 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Gross margin stability, five years | not computable | 2.3 pts | | | | |
| *annual revenue must exceed $100,000* | | | | | | |
| **Solvency, sleeve percentile 81.9** | | | | | | |
| Twelve-month failure probability | not computable | 0.05% | | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | | |
| Altman Z double-prime | (14.44) | 2.18 | | 84.7 | 565 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.08x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | 3.77x | | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 1.06x | 2.01x | | 79.1 | 663 | 2025-12-31 |
| **Growth and financing, sleeve percentile 95.2** | | | | | | |
| Revenue growth, three-year compound | (67.2%) | 6.4% | | 99.5 | 535 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 18.0% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 13.5% | | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | | |
| Asset growth, three years | (17.5%) | 5.1% | | 90.8 | 560 | 2025-12-31 |
| Net share issuance, one year | not computable | 0.5% | | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | | |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 3.8 months |
| Thin data | 6 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-06-02 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (26.7%) | (2.0%) | 30 |
| Distance from 52-week high | (73.6%) | (37.7%) | 14 |
| EBIT to enterprise value | not computable | 1.8% | |
| Free cash flow yield | not computable | 3.0% | |
| Book value to price | not computable | 0.30 | |
| Sales to price | not computable | 0.33 | |
| Composite equity issuance, five years | not computable | 4.2% | |
| Relative strength against the sector, log excess return | (0.58) | (0.29) | 30 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | pass |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $1.4M |
| Operating cash flow, four quarters | -$4.5M |
| Months of runway | 3.8 |
| Days since last periodic filing | 95 (10-Q received Aug 3, 2026) |
| Median daily dollar volume, 63 sessions | $0 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $102,911 | 2025-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 2 | assets | us-gaap:Assets | $20.9M | 2025-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 3 | net income | us-gaap:NetIncomeLoss | -$14.8M | 2025-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$4.6M | 2025-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 5 | assets | us-gaap:Assets | $28.8M | 2024-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 6 | revenue | us-gaap:Revenues | $124,157 | 2025-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 7 | gross profit | us-gaap:GrossProfit | -$31,866 | 2024-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 8 | revenue | us-gaap:Revenues | $20,729 | 2024-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 9 | current assets | us-gaap:AssetsCurrent | $1.1M | 2025-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 10 | current liabilities | us-gaap:LiabilitiesCurrent | $1.1M | 2025-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 11 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$67.5M | 2025-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 12 | operating income | us-gaap:OperatingIncomeLoss | -$14.0M | 2025-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 13 | book equity | us-gaap:StockholdersEquity | $7.6M | 2025-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 14 | liabilities | us-gaap:Liabilities | $13.3M | 2025-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 15 | operating income | us-gaap:OperatingIncomeLoss | -$13.2M | 2023-12-31 | 2025-03-07 | 10-K | 25-009568 |
| 16 | interest expense | us-gaap:InterestExpense | $144,193 | 2023-12-31 | 2024-03-08 | 10-K | 24-002897 |
| 17 | revenue | us-gaap:Revenues | $122,112 | 2023-12-31 | 2025-03-07 | 10-K | 25-009568 |
| 18 | revenue | us-gaap:Revenues | $3.5M | 2022-12-31 | 2024-03-08 | 10-K | 24-002897 |
| 19 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $34,561 | 2025-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$5.8M | 2024-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $21,331 | 2024-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$4.7M | 2023-12-31 | 2025-03-07 | 10-K | 25-009568 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $92,984 | 2023-12-31 | 2025-03-07 | 10-K | 25-009568 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$3.0M | 2022-12-31 | 2024-03-08 | 10-K | 24-002897 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $633,823 | 2022-12-31 | 2024-03-08 | 10-K | 24-002897 |
| 26 | depreciation amortization | us-gaap:Depreciation | $243,027 | 2025-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 27 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$14.8M | 2025-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 28 | income tax | us-gaap:IncomeTaxExpenseBenefit | $800 | 2025-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 29 | current assets | us-gaap:AssetsCurrent | $4.3M | 2024-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 30 | current liabilities | us-gaap:LiabilitiesCurrent | $4.0M | 2024-12-31 | 2026-03-30 | 10-K | 26-013579 |
| 31 | assets | us-gaap:Assets | $31.8M | 2023-12-31 | 2025-03-07 | 10-K | 25-009568 |
| 32 | assets | us-gaap:Assets | $37.1M | 2022-12-31 | 2024-03-08 | 10-K | 24-002897 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.